Loading...
Header Logo
Keywords
Last Name
Institution

SAID AKLI

TitleAssistant Professor
InstitutionMD Anderson
DepartmentExperimental Radiation Oncology
vCardDownload vCard

    Collapse ORNG Applications 
    Collapse Verify Publications

    Collapse Bibliographic 
    Collapse selected publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Faculty can login to make corrections and additions.
    List All   |   Timeline
    1. Karakas C, Biernacka A, Bui T, Sahin AA, Yi M, Akli S, Schafer J, Alexander A, Adjapong O, Hunt KK, Keyomarsi K. Cytoplasmic Cyclin E and Phospho-Cyclin-Dependent Kinase 2 Are Biomarkers of Aggressive Breast Cancer. Am J Pathol. 2016 07; 186(7):1900-1912. PMID: 27182644.
      View in: PubMed
    2. Caruso JA, Akli S, Pageon L, Hunt KK, Keyomarsi K. The serine protease inhibitor elafin maintains normal growth control by opposing the mitogenic effects of neutrophil elastase. Oncogene. 2015 Jul; 34(27):3556-67. PMID: 25195861.
      View in: PubMed
    3. Duong MT, Akli S, Macalou S, Biernacka A, Debeb BG, Yi M, Hunt KK, Keyomarsi K. Hbo1 is a cyclin E/CDK2 substrate that enriches breast cancer stem-like cells. Cancer Res. 2013 Sep 01; 73(17):5556-68. PMID: 23955388.
      View in: PubMed
    4. Akli S, Zhang XQ, Bondaruk J, Tucker SL, Czerniak PB, Benedict WF, Keyomarsi K. Low molecular weight cyclin E is associated with p27-resistant, high-grade, high-stage and invasive bladder cancer. Cell Cycle. 2012 Apr 01; 11(7):1468-76. PMID: 22441703.
      View in: PubMed
    5. Duong MT, Akli S, Wei C, Wingate HF, Liu W, Lu Y, Yi M, Mills GB, Hunt KK, Keyomarsi K. LMW-E/CDK2 deregulates acinar morphogenesis, induces tumorigenesis, and associates with the activated b-Raf-ERK1/2-mTOR pathway in breast cancer patients. PLoS Genet. 2012; 8(3):e1002538. PMID: 22479189.
      View in: PubMed
    6. Akli S, Van Pelt CS, Bui T, Meijer L, Keyomarsi K. Cdk2 is required for breast cancer mediated by the low-molecular-weight isoform of cyclin E. Cancer Res. 2011 May 01; 71(9):3377-86. PMID: 21385896.
      View in: PubMed
    7. Mittendorf EA, Liu Y, Tucker SL, McKenzie T, Qiao N, Akli S, Biernacka A, Liu Y, Meijer L, Keyomarsi K, Hunt KK. A novel interaction between HER2/neu and cyclin E in breast cancer. Oncogene. 2010 Jul 08; 29(27):3896-907. PMID: 20453888.
      View in: PubMed
    8. Akli S, Bui T, Wingate H, Biernacka A, Moulder S, Tucker SL, Hunt KK, Keyomarsi K. Low-molecular-weight cyclin E can bypass letrozole-induced G1 arrest in human breast cancer cells and tumors. Clin Cancer Res. 2010 Feb 15; 16(4):1179-90. PMID: 20145171.
      View in: PubMed
    9. Akli S, Van Pelt CS, Bui T, Multani AS, Chang S, Johnson D, Tucker S, Keyomarsi K. Overexpression of the low molecular weight cyclin E in transgenic mice induces metastatic mammary carcinomas through the disruption of the ARF-p53 pathway. Cancer Res. 2007 Aug 01; 67(15):7212-22. PMID: 17671189.
      View in: PubMed
    10. Barton MC, Akli S, Keyomarsi K. Deregulation of cyclin E meets dysfunction in p53: closing the escape hatch on breast cancer. J Cell Physiol. 2006 Dec; 209(3):686-94. PMID: 17001684.
      View in: PubMed
    11. Akli S, Keyomarsi K. Low-molecular-weight cyclin E: the missing link between biology and clinical outcome. Breast Cancer Res. 2004; 6(5):188-91. PMID: 15318923.
      View in: PubMed
    12. Akli S, Zheng PJ, Multani AS, Wingate HF, Pathak S, Zhang N, Tucker SL, Chang S, Keyomarsi K. Tumor-specific low molecular weight forms of cyclin E induce genomic instability and resistance to p21, p27, and antiestrogens in breast cancer. Cancer Res. 2004 May 01; 64(9):3198-208. PMID: 15126360.
      View in: PubMed
    13. Wingate H, Bedrosian I, Akli S, Keyomarsi K. The low molecular weight (LMW) isoforms of cyclin E deregulate the cell cycle of mammary epithelial cells. Cell Cycle. 2003 Sep-Oct; 2(5):461-6. PMID: 12963845.
      View in: PubMed
    14. Akli S, Keyomarsi K. Cyclin E and its low molecular weight forms in human cancer and as targets for cancer therapy. Cancer Biol Ther. 2003 Jul-Aug; 2(4 Suppl 1):S38-47. PMID: 14508079.
      View in: PubMed
    15. Akli S, Zhan S, Abdellatif M, Schneider MD. E1A can provoke G1 exit that is refractory to p21 and independent of activating cdk2. Circ Res. 1999 Aug 20; 85(4):319-28. PMID: 10455060.
      View in: PubMed
    16. Guidotti J, Akli S, Castelnau-Ptakhine L, Kahn A, Poenaru L. Retrovirus-mediated enzymatic correction of Tay-Sachs defect in transduced and non-transduced cells. Hum Mol Genet. 1998 May; 7(5):831-8. PMID: 9536087.
      View in: PubMed
    17. Lisovoski F, Akli S, Peltekian E, Vigne E, Haase G, Perricaudet M, Dreyfus PA, Kahn A, Peschanski M. Phenotypic alteration of astrocytes induced by ciliary neurotrophic factor in the intact adult brain, As revealed by adenovirus-mediated gene transfer. J Neurosci. 1997 Oct 01; 17(19):7228-36. PMID: 9295369.
      View in: PubMed
    18. Haase G, Kennel P, Pettmann B, Vigne E, Akli S, Revah F, Schmalbruch H, Kahn A. Gene therapy of murine motor neuron disease using adenoviral vectors for neurotrophic factors. Nat Med. 1997 Apr; 3(4):429-36. PMID: 9095177.
      View in: PubMed
    19. Akli S, Guidotti JE, Vigne E, Perricaudet M, Sandhoff K, Kahn A, Poenaru L. Restoration of hexosaminidase A activity in human Tay-Sachs fibroblasts via adenoviral vector-mediated gene transfer. Gene Ther. 1996 Sep; 3(9):769-74. PMID: 8875224.
      View in: PubMed
    20. Kahn A, Haase G, Akli S, Guidotti JE. [Gene therapy of neurological diseases]. C R Seances Soc Biol Fil. 1996; 190(1):9-11. PMID: 8881264.
      View in: PubMed
    21. Cohen-Tannoudji M, Marchand P, Akli S, Sheardown SA, Puech JP, Kress C, Gressens P, Nassogne MC, Beccari T, Muggleton-Harris AL, et al. Disruption of murine Hexa gene leads to enzymatic deficiency and to neuronal lysosomal storage, similar to that observed in Tay-Sachs disease. Mamm Genome. 1995 Dec; 6(12):844-9. PMID: 8747922.
      View in: PubMed
    22. Lisovoski F, Peltekian E, Akli S, Vigne E, Bouchard C, Haase G, Dreyfus P, Perricaudet M, Kahn A, Peschanski M. Using adenoviral vectors to transfer the CNTF gene into the CNS. Restor Neurol Neurosci. 1995 Jan 01; 8(1):45-6. PMID: 21551805.
      View in: PubMed
    23. Lisovoski F, Cadusseau J, Akli S, Caillaud C, Vigne E, Poenaru L, Stratford-Perricaudet L, Pericaudet M, Kahn A, Peschanski M. In vivo transfer of a marker gene to study motoneuronal development. Neuroreport. 1994 May 09; 5(9):1069-72. PMID: 8080960.
      View in: PubMed
    24. Poenaru L, Akli S. Molecular epidemiology of Tay-Sachs disease in Europe. Biomed Pharmacother. 1994; 48(8-9):341-6. PMID: 7858168.
      View in: PubMed
    25. Caillaud C, Akli S, Vigne E, Koulakoff A, Perricaudet M, Poenaru L, Kahn A, Berwald-Netter Y. Adenoviral vector as a gene delivery system into cultured rat neuronal and glial cells. Eur J Neurosci. 1993 Oct 01; 5(10):1287-91. PMID: 8275231.
      View in: PubMed
    26. Peschanski M, Lisovoski F, Akli S, Caillaud C, Wahrman P, Weber-Benarous A, Vigne E, Stratford-Perricaudet L, Perricaudet M, Kahn A. [Gene transfer with a therapeutic purpose in the central nervous system]. Nouv Rev Fr Hematol. 1993 Jun; 35(3):299-300. PMID: 8337147.
      View in: PubMed
    27. Akli S, Caillaud C, Vigne E, Stratford-Perricaudet LD, Poenaru L, Perricaudet M, Kahn A, Peschanski MR. Transfer of a foreign gene into the brain using adenovirus vectors. Nat Genet. 1993 Mar; 3(3):224-8. PMID: 8485577.
      View in: PubMed
    28. Akli S, Chelly J, Kahn A, Poenaru L. A null allele frequent in non-Jewish Tay-Sachs patients. Hum Genet. 1993 Feb; 90(6):614-20. PMID: 8444467.
      View in: PubMed
    29. Akli S, Boue J, Sandhoff K, Kleijer W, Vamos E, Young E, Gatti R, Di Natale P, Motte J, Vanier MT, et al. Collaborative study of the molecular epidemiology of Tay-Sachs disease in Europe. Eur J Hum Genet. 1993; 1(3):229-38. PMID: 8044648.
      View in: PubMed
    30. Akli S, Chomel JC, Lacorte JM, Bachner L, Kahn A, Poenaru L. Ten novel mutations in the HEXA gene in non-Jewish Tay-Sachs patients. Hum Mol Genet. 1993 Jan; 2(1):61-7. PMID: 8490625.
      View in: PubMed
    31. Poenaru L, Akli S, Rocchiccioli F, Eydoux P, Zamet P. Human beta-mannosidosis: a 3-year-old boy with speech impairment and emotional instability. Clin Genet. 1992 Jun; 41(6):331-4. PMID: 1623631.
      View in: PubMed
    32. Chelly J, Gilgenkrantz H, Hugnot JP, Hamard G, Lambert M, Récan D, Akli S, Cometto M, Kahn A, Kaplan JC. Illegitimate transcription. Application to the analysis of truncated transcripts of the dystrophin gene in nonmuscle cultured cells from Duchenne and Becker patients. J Clin Invest. 1991 Oct; 88(4):1161-6. PMID: 1918370.
      View in: PubMed
    33. Akli S, Chelly J, Lacorte JM, Poenaru L, Kahn A. Seven novel Tay-Sachs mutations detected by chemical mismatch cleavage of PCR-amplified cDNA fragments. Genomics. 1991 Sep; 11(1):124-34. PMID: 1837283.
      View in: PubMed
    34. Akli S, Chelly J, Mezard C, Gandy S, Kahn A, Poenaru L. A "G" to "A" mutation at position -1 of a 5' splice site in a late infantile form of Tay-Sachs disease. J Biol Chem. 1990 May 05; 265(13):7324-30. PMID: 2139660.
      View in: PubMed
    35. Poenaru L, Mezard C, Akli S, Oury JF, Dumez Y, Boue J. Prenatal diagnosis of mucolipidosis type II on first-trimester amniotic fluid. Prenat Diagn. 1990 Apr; 10(4):231-5. PMID: 1973293.
      View in: PubMed
    36. Gandy S, Castelnau L, Akli S, Kahn A, Poenaru L. Msp1 RFLP in the human hexosaminidase beta peptide (Hex B) gene. Nucleic Acids Res. 1989 Aug 25; 17(16):6761. PMID: 2476722.
      View in: PubMed
    37. Poenaru L, Castelnau L, Besançon AM, Nicolesco H, Akli S, Theophil D. First trimester prenatal diagnosis of metachromatic leukodystrophy on chorionic villi by 'immunoprecipitation-electrophoresis'. J Inherit Metab Dis. 1988; 11(2):123-30. PMID: 2902245.
      View in: PubMed
    38. Erratum. Human Molecular Genetics. 2:496.
    39. Using adenoviral vectors to transfer the CNTF gene into the CNS. Restorative Neurology and Neuroscience. 8:45-46.
    40. The serine protease inhibitor elafin maintains normal growth control by opposing the mitogenic effects of neutrophil elastase. Oncogene. 34:3556-3567.
    41. MALADIES DE TAY-SACHS ET DE SANDHOFF. Medecine/Sciences. 8:797-804.
    42. PCRBASE. Medecine/Sciences. 9:1256-1261.
    43. L'ADENOVIRUS. Medecine/Sciences. 9:236-237.
    44. Ten novel mutations in the HEXA gene in non-jewish tay-sachs patients. Human Molecular Genetics. 2:496.
    AKLI's Networks
    Click the "See All" links for more information and interactive visualizations!
    Concepts Expand Description
    _
    Co-Authors Expand Description
    _
    Similar People Expand Description
    _
    Same Department Expand Description